
    
      The aim of the study is to assess the efficacy of several subcutaneous doses of nemolizumab
      in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving topical
      corticosteroids, who were not adequately controlled with topical treatments.
    
  